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Abstract
A risk score for lung cancer derived from genetic and clinical data has been shown to 
motivate smokers to quit. However, smokers with a relatively low (but not insignifi‐
cant) risk score are more likely to carry on smoking. To understand this observation, 
the balance between smoking cessation motivators and de‐motivators must be under‐
stood. A relatively low risk score can act as a de‐motivator. Other de‐motivators that 
have been recorded and were observed by researchers involved in this project were: 
nicotine addiction and fear of withdrawal symptoms, optimism bias, confirmation 
bias, attentional bias, post‐traumatic stress disorder (PTSD), anxieties about smoking 
cessation and weight gain, side effects of smoking cessation therapy, fatalism, peer 
pressure and lack of family cohesion. This long list of de‐motivators serves to empha‐
size the complexity of the psychological make‐up of the individual smoker. This is 
illustrated by a set of case histories (anonymised for confidentiality). The future use of 
a risk score as a smoking cessation motivator is discussed and suggestions are made 
as to how a risk score could be made more effective including inclusion of scoring for 
cardiovascular risk.
Keywords: smoking cessation, genetic testing, lung neoplasms, primary health care
1. Introduction
The reasons why smokers either continue to smoke or stop smoking are diverse and every 
case is probably unique. However, there is a basic truth in that there is a constant seesaw 
between smoking cessation motivators and the rather less well understood de‐motivators. 
The importance of de‐motivators is illustrated by the simple fact that over 60% of smok‐
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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ers say they would like to quit but most seem somehow unable to do so [1, 2]. The obvi‐
ous explanation is that this is due to nicotine addiction but this may be only one of many 
de‐motivators.
In 2014, my colleagues and I at the University of Surrey, United Kingdom (UK), carried 
out research into smoking cessation. We recruited 67 smokers who wanted to quit from 
a primary care database of 32,000 (Table 1) and randomized them to either a control 
group or a test group. The test group had an additional motivator to quit. This was the 
Respiragene risk score for lung cancer derived from a genetic test (19 single‐nucleotide 
polymorphisms (SNPs) and one deletion mutation) and clinical criteria including history 
of chronic obstructive pulmonary disease, family history of lung cancer, and age. Both 
groups attended 8 weekly smoking cessation clinics which took place at the same primary 
care venue but with test group and control group attended on different weekdays. We 
published our protocol and outcome measures a priori [3]. Primary outcome was smoking 
cessation after 6 months.
During our research, we found that 36% of smokers had stopped smoking and were still not 
smoking after 6 months. Of the 64% who were still smoking at 6 months, all but two partici‐
pants planned to stop smoking at some time in the future and 30% had cut down substantially 
(by 10 or more cigarettes/day) [4].So why don't they just quit?
Our hypothesis was that when participants were told their lung cancer risk, this would tend 
to outbalance any de‐motivators such as issues around nicotine addiction (Figure 1) and give 
a high 6‐month quit rate. However, we were probably underestimating the potency of known 
and unknown de‐motivators. It certainly cannot be entirely due to nicotine addiction because 
varenicline blocks the physical addiction and prevents most withdrawal symptoms and yet 
50–75% of subjects taking varenicline will still be smoking 6 months later [5, 6]. There must, 
therefore, be more to it than nicotine addiction.
Demographic/smoking feature Test group (n=36) Control group (n=31) p‐Values (test)
Gender: female 55.6% 53.3% 0.747 (Chi‐square)
Mean age (at start of study) 49.7 49.0 0.812 (Unpaired t)
Mean age at completion of 
education
18.4 18.5 0.971 (Unpaired t)
Years in education (excluding 
interruptions)
22.8 26.2 0.517 (Unpaired t)
Pack years 32.0 28.9 0.396 (Unpaired t)
Cigarettes/day at start 18.1 18.1 0.993 (Unpaired t)
Table 1. Demographic and baseline smoking data for Respiragene trial.
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2. The Respiragene project
As already reported [4], the 6‐month quit rate in our Respiragene trial was more dependent 
on the risk score than we had expected. The laboratory reported the Respiragene risk score 
as three categories: average risk of lung cancer, high risk of lung cancer, and very high risk of 
lung cancer. Only non‐smokers and ex‐smokers can achieve the category “low risk”. We were 
also able to estimate lifetime risk as a percentage (i.e., a 50% lifetime risk meant that the risk of 
lung cancer was like tossing a life/death coin). The 6‐month quit rate results are summarized 
in Figure 2. However, assessing the balance of motivators and de‐motivators was included in 
secondary outcomes. The relative importance of ten smoking cessation motivators was esti‐
mated using a feedback questionnaire at 8 weeks and again at 6 months. The results show the 
perceived importance of these motivators (Figure 3).
From taking notes on comments from patients during counselling and from responses to open‐
ended questions in feedback questionnaires that participants completed, we were able to clarify 
the roles of some of these de‐motivating factors. Most smokers have two main de‐motivators:
1. Nicotine addiction and fear of withdrawal symptoms [7–9]. Nicotine has been shown to 
be as addictive as illegal drugs such as morphine and cocaine.
2. Optimism bias [10–13].Tendency to underestimate the health risks of smoking and the 
feeling “It'll never happen to me”.
We expected that our study would confirm the hypothesis that being told a risk score for lung 
cancer would cancel out both nicotine addiction and optimism bias in at least 50% of partici‐
pants. An earlier study (n = 99) using the Respiragene risk score had shown that smokers were 
more likely to quit compared with a control group whatever risk score they were given [14]. 
However, these participants were recruited from a hospital in New Zealand. We carried out a 
similar trial in a UK primary care setting. A surprise finding from our trial was that although 
all but one of the participants with a very high risk score had stopped smoking at 6 months, 
participants with an average risk score were more likely to be smoking than controls (Figure 2).
Figure 1. For smokers: the seesaw of destiny. The balance between motivators and de‐motivators determines success or 
failure for smokers trying to quit.
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Figure 2. The blue “glass ceiling” represents the quit rate for the control group. Quit rate at 6 months for controls was 
57%. Subjects with an average risk score for lung cancer (only non‐smokers and ex‐smokers are assessed as “low risk 
score”) had a lower quit rate than controls, and a “moderately high” quit rate was no better but difficult to judge due 
to small numbers (only 4). However, all but one of the nine subjects with a “very high” risk score (equivalent to 50% 
lifetime risk of lung cancer) had quit at 6 months giving an 89% quit rate.
Figure 3. Mean values for motivators and influences that have helped to reduce or stop smoking: “Please score each 
of the items below according to how strong an influence they have been in helping you to quit smoking”. Scores for 
motivators for individual participants were calculated as percentages of the sum of total scores of the individual and 
mean values calculated from these percentage scores.
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The test subjects with an average risk score demonstrated a quit rate that was significantly 
lower than the quit rate in the control group (p = 0.03) which suggests that they had been de‐
motivated and encouraged to think that it was safe to carry on smoking because their lifetime 
risk was perceived as “not so bad”. Or to put it another way, their optimism bias has been 
reinforced by their average risk score! Psychologists refer to this phenomenon as (No. (iii)) 
confirmation bias [15] and explain that when a subject has two conflicting ideas in their head 
(i.e., smoking is too risky versus the risk of smoking is exaggerated), this is intolerable—a 
phenomenon known as cognitive dissonance [16]. This mental discomfort can only be solved 
by ditching one idea and giving undue prominence to the other. A classic example is the 
smoker who responds to a challenge about the risks of his habit by saying: “Uncle Charlie 
smoked like a trouper and lived to be 90”. Any evidence to the contrary, such as other smok‐
ers in the family who died young, is conveniently ignored.
Other possible factors that make it difficult to quit that we noted in our participants and 
which have been previously recognized by other researchers in this field were as follows:
1. Attentional bias [17, 18]. The smoker is plagued by recurrent thoughts about the pleasures 
of smoking that serve to increase craving for the next cigarette.
2. Post‐traumatic stress disorder (PTSD) [19–21]. This is a mental health condition caused 
by a traumatic event such as rape, warfare experiences, and other near death experiences 
such as road traffic accidents and industrial accidents. The subjects experience distressing 
dreams and flashbacks, and they are more likely to become heavily addicted smokers.
3. Anxieties about smoking cessation and weight gain [22, 23]. This is an issue for many 
female smokers who start smoking when they are relatively young to control their weight. 
Later in life, they may try to quit but revert to smoking when they put on weight.
4. Side effects of smoking cessation therapy [24–26]. Patients using pharmaceuticals such as 
nicotine replacement therapy (NRT) patches or nicotine blocking drugs frequently report 
side effects. Once they have experienced a side effect, they usually revert to smoking.
5. Fatalism [27, 28]. This is the attitude that “What will be will be”. These smokers either feel 
they have little or no control over outcomes such as lung cancer or they simply do not care 
if they are destined to develop a smoking‐related disease.
6. Peer pressure [29, 30]. The influence of fellow workers on smoking can be a decisive factor. 
All the emphasis has been on peer pressure in adolescence and initiation of smoking, but 
peer pressure can be equally important in the adult work force.
7. Lack of family cohesion [31, 32]. Research has shown that family cohesion is associated 
with concerns about passive smoking and smoking cessation. Conversely, lack of family 
cohesion is associated with a significantly higher incidence of persistent smoking.
8. Inadequacy of the risk score as a motivator. Our own research, as described above, sug‐
gests that a risk score for a single disease (lung cancer in this case) is not a powerful enough 
motivator to cancel out de‐motivators in 64% of smokers, especially if the risk score is “low 
average” when they may be falsely reassured and continue smoking.




To preserve confidentiality, the case histories I present here have been altered (age, gender, 
and circumstantial details) so that the participants in our research project are unrecognizable. 
However, basic clinical details have been preserved as far as possible. These cases help to 
demonstrate why some smokers cannot quit, despite stating that they would like to.
2.1.1. Case no. 1.: lifetime risk of lung cancer = 35%
This participant was a young housewife who was stressed by having to care for two mildly 
hyperactive small boys aged 3 and 5 and was still smoking 15 cigarettes/day at 6 months. She 
seemed falsely reassured by the 35% lifetime risk commenting: “only 35% that's not so bad”. 
When I gave her an analogy: “What if I told you that if you carried on living in your present 
house, you stood a 35% chance of being murdered in your bed, but if you moved to a house 
in the next road the risk would drop to 1%”. She hesitated a moment then said: “But doctor, 
that's completely different”.
2.1.1.1. Commentary
A 35% lifetime risk is less than the risk of tossing a life/death coin but close enough to be 
worrying. So why wasn't this patient worried? Her hesitation suggests cognitive dissonance 
[16]. That is two competing ideas buzzing around in your head. For stability and well‐being, 
one of the competing ideas must give way. Her most comforting solution was to accept that 
the 35% risk of lung cancer was nothing like the risk of being murdered in your bed. Well, of 
course, it is a different scenario but the risk of death is identical. This is also a good example 
of confirmation bias [15]. She managed to confirm her feeling that a 35% risk was “not so bad” 
by rejecting my analogy.
2.1.2. Case no. 2.: lifetime risk of lung cancer = 10%
This participant had been a mature medical student who qualified in his mid 30s. Soon after 
qualifying, he was at BMA House, Tavistock Square, in 2007, when the suicide bomber deto‐
nated on the top deck of a bus in Tavistock Square, and he was the first doctor on the scene. 
Although he was a non‐smoker at the time, he found the only way to cope with flash backs 
and other PTSD symptoms related to this horrific incident was to become a habitual smoker. 
He is now a part‐time psychiatrist near retirement and was still smoking 10 cigarettes/day at 
the 6‐ month follow‐up.
2.1.2.1. Commentary
This participant started smoking for the first time aged 40 years, which is unusual. However, 
the circumstances were also unusual. Although this is obviously linked to post‐traumatic 
stress disorder (PTSD), there may be less dramatic and less obvious versions of PTSD that 
fuel the smoking habit such as unreported domestic abuse.
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2.1.3. Case no. 3.: lifetime risk of lung cancer = 19%
This participant was a 23‐year‐old woman who worked as a stable maid. She had quit at 
8 weeks and she had always seemed highly motivated. However, she sustained a compound 
fracture to her right tibia when she was kicked by a horse. As a result, she was stuck at home, 
off sick, with the injury for some time. All the pain and worry and the boredom of being at 
home all the time is what started her back on the cigarettes (10/day)—they made it all a bit 
more bearable.
2.1.3.1. Commentary
Although this participant cites pain and boredom as the reasons for relapsing to smoking, 
there were also features of PTSD. Her failure to quit was surprising as she was the “leading 
light” of the test group. She was the first in her group to quit and gently encouraged other 
participants. Perhaps this case illustrates how PTSD acts as a very powerful de‐motivator.
2.1.4. Case no. 4.: control (no risk score)
This 58–year‐old woman in the control group did not seem to have much of a problem quit‐
ting after a lifetime as a smoker (started aged 14 year) but she told me, at the 6‐month follow‐
up that it was far from easy and described it as being like bereavement. It is, quite literally, 
as difficult to deal with as the death of someone very close to you. On the other hand, her 
lead motivator was concern about the affects of side‐stream smoke on someone very dear to 
her—her new baby grandson.
2.1.4.1. Commentary
This participant was remarkably open and honest about her feelings, and it is certainly sober‐
ing to think that smoking cessation is as difficult to cope with as suffering a bereavement. 
However, the fact that her main motivator was concern for her grandchild is very significant. 
Researchers have shown that family cohesion is associated with a lower incidence of smoking 
and lack of family cohesion with a very high incidence (70%) of smoking [32]. Family cohe‐
sion and awareness and acceptance of the health hazards of side‐stream smoke correlated 
(p < 0.01) in a paper from Texas in 2010 [31]. Two other participants mentioned the influence 
of grandchildren in relation to passive smoking and their decision to quit. Altogether, 8/67 
(12%) of our participants mentioned passive smoking and family as a key motivator without 
prompting (in response to an open‐ended question asking for “further comments“).
2.1.5. Case no. 5.: lifetime risk of lung cancer >50%
This 48‐year‐old woman, who had recently been through a stressful divorce, was unable to 
work due to the debilitating effects of Crohn's disease. She was well aware that smoking ces‐
sation would probably improve her Crohn's symptoms. She started on varenicline but had 
to stop taking it after 3 days due to an acute exacerbation of Crohn's symptoms. She never 
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returned to the clinic and was still smoking 12/day at the 6‐month follow‐up saying: “This is 
my only way of coping with boredom”.
2.1.5.1. Commentary
The impression from this patient was that she had simply “given up”. There are varying 
degrees of fatalism like this exhibited by smokers [27]. She might have been able to fight back 
with the help of varenicline, unfortunately she had gastrointestinal side effects that she inter‐
preted as an exacerbation of her Crohn's disease so stopped taking varenicline after 3 days. In 
her case, the varenicline side effects seemed to a significant de‐motivator.
2.1.6. Case no. 6.: lifetime risk of lung cancer 58%
This 35‐year‐old single man in a high‐powered office job had managed to stop smoking for 
5 years when his younger brother died of lung cancer. This was the third 1st degree relative to 
die from lung cancer. However, his current work ethos was one in which “everyone smoked” 
and now he was back on 15 cigarettes/day. Despite the family history and a high risk score 
he was still smoking 15 cigarettes/day at the 6‐month follow‐up. He blamed “work stress and 
peer pressure” for his inability to quit.
2.1.6.1. Commentary
This subject's inability to quit was really puzzling, and he himself was puzzled by it. There 
may have been several de‐motivating issues but peer pressure at work was certainly very 
significant in his case.
3. Genetics and smoking behaviour
Nicotine, cannabinoids, and cocaine act as insecticides to protect plants from insect attack. 
Mammals that eat plants have evolved to tolerate these chemicals but only humans have 
developed the habit of burning and inhaling plants containing these toxic chemicals. 
Archaeologists have found evidence for this habit going back into prehistory [33]. There is 
even evidence of genetic adaptions to nicotine specific to humans [34]. Edward Hagan, pro‐
fessor of Anthropology at Washington State University, argues that there is a balance of ben‐
efits and costs to smoking tobacco. Nicotine must have some advantages that outweigh the 
health costs in some circumstances. Our ancestors may have found the effects of nicotine on 
the brain beneficial in times of stress and hunger but Hagan argues that nicotine's greatest 
evolutionary advantage may have been efficacy as an anti‐helminth drug, especially in con‐
trolling those helminth parasites that migrate through the lungs [35].
It is no surprise, therefore, that there are human genes that relate to smoking behaviour. A recent 
review estimated that, according to twin studies, 75% of behavioural variation (variation in smok‐
ing initiation, persistence, and cessation rates) is genetically determined [36]. However, only about 
5% of this variation can currently be explained by known gene variants, mainly single‐nucleotide 
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polymorphisms (SNPs) but 19% of the variation in smoking initiation can be explained by known 
SNPs. Research is ongoing in this area with the hope that identification of further SNPs and other 
gene variants will improve our understanding of smoking behaviour and smoking cessation de‐
motivators leading to new effective treatments to aid smoking cessation [8, 36]. This research 
includes increasing our understanding of epigenetic off/on gene switching in determining vari‐
ous aspects of smoking behaviour and pathologies associated with smoking [8, 37].
An understanding of the genetics and epigenetics of PTSD is very relevant to helping smokers 
to quit, especially those who seem to be hardened nicotine addicts. Twin studies have shown 
that only 20–30% of subjects exposed to severe trauma develop PTSD [38]. Less than 50% of 
women who experience violent rape develop overt PTSD. Genetic studies have shown that a 
combination of four or more high‐risk alleles (single gene variants) confer a sevenfold increase 
in the risk of PTSD following trauma [38]. However, lesser degrees of PTSD associated with 
cigarette smoking [19] may also have a genetic component. Further research in this area seems 
likely to overlap with research focused on the genetics of smoking behaviour and is likely to 
lead to new strategies in treatment of both PTSD and in helping to achieve smoking cessation.
4. Discussion
I had been unaware of the possibility that PTSD could be a common barrier to smoking ces‐
sation. Beckham et al. [20] showed that there is a significant difference between PTSD and 
non‐PTSD smokers during attempts to quit with the PTSD subjects being more likely to lapse 
after 1 week (Figure 4). There is also a growing body of research that shows that we may only 
recognize the more obvious instances such as PTSD in war veterans and rape victims. The 
literature is unclear on the incidence of PTSD in the general population with reports ranging 
from 1 to 5%. If we take 3% as a median value, it is likely that a sample of lifelong non‐smok‐
ers would exhibit a lower incidence (approx. 2%) so that the incidence of overt PTSD is 3 
times higher in smokers. A paper by Matthews et al. [19] showed that 6.7% of smokers are 
suffering from overt PTSD but also showed that another 73% of their study group of cur‐
rent smokers (n = 342) had symptom scores suggestive of some degree of stress or as they 
termed it: “sub‐threshold PTSD”. There was no correlation between smoking and anhedonia. 
Only 20% of their sample was completely negative for their PTSD score. Perhaps sub‐thresh‐
old PTSD includes unreported domestic abuse and bullying at work. Domestic violence has 
been recorded as a cause of PTSD‐related smoking [39]. There is evidence from research by 
neuropsychiatry that nicotine inhibits negative symptoms experienced in PTSD and that the 
positive “feel good” effects of nicotine is relatively insignificant [19, 21]. Further research is 
needed to clarify the differences in PTSD scoring between smokers and non‐smokers and to 
determine what can be done to help this category of refractory smokers.
Smokers who are concerned about weight gain will need special help but sometimes coun‐
selling and dietary advice are ineffective. Hurt et al. at The Mayo Clinic, USA, are currently 
researching the combined pharmacological approach of varenicline and lorcaserin (a new 
anti‐obesity drug) for overweight smokers who want to quit. Early results are encouraging 
(personal communication from Hurt).
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Do smokers who experience side effects from smoking cessation drugs tend to give up trying 
to quit as seemed to be the case with case 5? The literature is unclear on this issue. However, 
the Respiragene project certainly showed a significant difference between those that had 
been able to persist with their original smoking cessation prescription (varenicline or nicotine 
replacement therapy) and those who had stopped due to side effects (Table 2) with quit rates 
at 6 months of 42.6 and 15.3%, respectively (p = 0.01).
Studies linking work stress to smoking are equally balanced between those that do and do 
not show a link. One of the best studies, however, from Finland shows an odds ratio of 1.28 
(p < 0.01) for smoking where there is a high imbalance between effort and reward consistent 
with work stress [40]. Concerns about passive smoking in the family home have received a 
Figure 4. Survival curves for smoking lapse in PTSD (n = 55) versus non‐PTSD (n = 52) in first week of a quit attempt 
showing that PTSD is associated with a higher smoking relapse rate (from Beckham et al. [16]).
Stopped smoking at 6‐month follow‐up Total
Lost to follow‐up Yes No
Prescription history unknown 2 0 5 7
Persisted with first prescription 3 20 24 47
Stopped first prescription 0 2 11 13
Total 5 22 40 67
χ2  = 6.6, p = 0.01.
Table 2. Smoking cessation outcome for subjects who stopped smoking cessation therapy due to side effects compared 
with subjects who had persisted with smoking cessation therapy.
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good deal of publicity recently despite attempts by the tobacco industry to play down the 
risks [41]. Finding that 12% of our participants mentioned this as a key smoking cessation 
motivator was not, therefore, unexpected. Just as family cohesion is a factor here, conversely 
lack of family cohesion is emerging as a significant de‐motivator [31, 32].
Fatalism and peer pressure are well known as factors that encourage smoking but the precise 
role of adult peer pressure in the workplace needs further research. A review of smoking ces‐
sation in the workplace has outlined strategies for influencing the workplace ethos to improve 
attitudes and introducing workplace smoking cessation programmes and smoking cessation 
inducements [42].
The efficacy of a risk score such as the Respiragene risk score as a smoking cessation moti‐
vator could, perhaps, be improved if it included cardiovascular risk as well as lung cancer 
risk. A recent paper estimated that smokers double the risk of an early death from car‐
diovascular events but that risk reverts to normal after 2 years of smoking cessation [43]. 
Personalized data on cardiovascular risk could be included in the risk score in future. This 
might include genetic risk factors such as the apolipoprotein E4 gene but clinical factors 
such as family history, blood pressure, body mass index, lipid profile, and HbA1C would 
be equally important.
5. Conclusions
Fear of lung cancer can certainly act as a powerful motivator as demonstrated by the high quit 
rate for subjects with a very high Respiragene risk score. However, the problem with a per‐
sonalized risk score is that if the risk is relatively low, it may act as a de‐motivator. Including 
a personalized risk score for life‐threatening cardiovascular events (stroke and myocardial 
infarction) might help to counter this problem, especially as most smokers will be given a risk 
score round about the mean of 100% increase in risk of a fatal event. However, even the most 
persuasive smoking cessation motivator is unlikely to overcome powerful de‐motivators such 
as PTSD or weight control issues in about 20% of smokers. If a smoker in this category who 
may have attempted to quit 2 or 3 times already is still determined to quit, the de‐motiva‐
tor that is standing in the way of success must be addressed and this may need intense one 
to one counselling and/or a pharmacological intervention. New and better pharmacological 
approaches are likely to result from genetic studies on smoking behaviour.
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